NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Phase 1
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: ImiquimodBiological: NY-ESO-1 protein
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 9
- Registration Number
- NCT00142454
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Phase 2
Terminated
- Conditions
- Synovial Sarcoma
- Interventions
- Biological: ipilimumab
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 6
- Registration Number
- NCT00140855
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 2
Completed
- Conditions
- Peritoneal Cavity CancerFallopian Tube CancerOvarian Cancer
- Interventions
- Biological: rV-NY-ESO-1 vaccineBiological: rF-NY-ESO-1 vaccine
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 23
- Registration Number
- NCT00112957
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2005-03-22
- Last Posted Date
- 2010-11-05
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 9
- Registration Number
- NCT00106158
- Locations
- 🇯🇵
Dept. of Immunology, Okayama University School of Medicine and Dentistry, Okayama, Japan
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Phase 1
Completed
- Conditions
- Kidney Cancer
- Interventions
- Biological: Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
- First Posted Date
- 2004-08-12
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 15
- Registration Number
- NCT00003102
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
Phase 1
Completed
- Conditions
- Lung Cancer
- Interventions
- Biological: monoclonal antibody hu3S193
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 10
- Registration Number
- NCT00084799
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Phase 1
Terminated
- Conditions
- Ovarian Cancer
- Interventions
- Biological: Monoclonal antibody hu3S193
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 1
- Registration Number
- NCT00006099
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Phase 1
Completed
- Conditions
- Ovarian Cancer
- Interventions
- Biological: 90Y-hu3S193Biological: 111In-hu3S193
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 7
- Registration Number
- NCT00072410
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Phase 1
Completed
- Conditions
- Transitional Cell Carcinoma
- Interventions
- Biological: TICE®-strain BCGBiological: NY-ESO-1 proteinBiological: sargramostim
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 6
- Registration Number
- NCT00070070
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1
Completed
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer
- Interventions
- Biological: NY-ESO-1 peptide vaccine
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 9
- Registration Number
- NCT00066729
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath